While AIs are a key treatment for postmenopausal women with hormone receptor‐positive early‐stage breast cancer, the development of joint pain and muscle stiffness limits patients' quality of life and compliance with therapy, highlighting the need for effective treatment strategies [1, 3, 7, 31, 32]. The gene discussed is NR4A1; the disease is breast cancer.